frespaciguat

Small molecule

Earlyevidence

Evidence outlook

Mid-stage studies underway, no completed readout

Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Other / comorbidity
NCT04732221 · Merck Sharp & Dohme LLC
2021-05-19 – 2024-07-02 · Pulmonary Arterial Hypertension, Hypertension, Pulmonary
What this study did
Phase 2 (1)
Pulmonary Hypertension
NCT05612035 · Merck Sharp & Dohme LLC
2023-03-16 – 2027-05-01 · Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
What this study did
Phase 1 (4)
Pulmonary Hypertension
NCT04370873 · Merck Sharp & Dohme LLC
2020-06-05 – 2022-01-12 · Pulmonary Hypertension
What this study did
Other / comorbidity
NCT03744637 · Merck Sharp & Dohme LLC
2019-01-18 – 2020-12-11 · Pulmonary Arterial Hypertension
What this study did
NCT04425733 · Merck Sharp & Dohme LLC
2020-07-07 – 2020-11-10 · Coronavirus Disease 2019 (COVID-19), Pneumonia, Hypoxemia
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.